Univariate analysis was performed using the log-rank test.21  Factors that were potential predictive of OS (P < .05) were entered into a multivariate analysis using the Cox proportion hazards model.22  All statistical analysis was performed using SPSS version 10.0 (SPSS, Chicago, IL). At a median follow-up of 4 years, the PFS and OS are 28% and 34% by intention to treat and 39% and 45% for only those patients with chemosensitive disease. We also combined the data from all trials.

With respect to the EFS and PFS end points, the Kaplan-Meier curves of the various IPI groups differed significantly for all three trial populations. Rituximab significantly improved the treatment outcome within each of the four IPI groups. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Patient characteristics of 150 patients with DLBCL before ICE chemotherapy.

Note: IPI results are included for historical comparisons only. Compare the overall and disease-free/relapse-free survival of patients treated with these regimens. Prognostic factors in aggressive Non-Hodgkin's lymphoma: Who has “high-risk” disease? This subgroup of patients may be the source of excess late distant relapses seen in the ASH update of SWOG 8736. Guglielmi et al29  performed a retrospective analysis of 474 patients with relapsed DLCL from 47 centers in Italy.29  A variety of salvage regimens were used, and ultimately only 20% (95 patients) underwent HDT with ASCT. However, only 16 patients in the ASCT group had high-intermediate or high-risk disease by the aaIPI, which may have limited the power of the analysis and consequently the predictive value of the aaIPI. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. ASCO Connection The intent-to-treat OS and PFS of 18% and 16%, respectively, compare favorably with the reported OS/PFS (5%-10%) for patients with the poorest risk in previous models.6,29  Approximately 25% of chemosensitive patients in the high-risk group can expect long-term survival.

Abbreviations: MInT, MabThera International Trial; MegaCHOEP, dose-escalated regimen of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; RICOVER-60, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab for patients older than age 60 years; EFS, event-free survival; PFS, progression-free survival; OS, overall survival; aaIPI, age-adjusted International Prognostic Index. There is in depth information about the two versions of this lymphoma prognostic index and also about an age adjusted … The IPI factor “more than one extranodal involvement” did not show prognostic relevance in our data set.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Reviewers Subscribers This model was useful in shaping the role of HDT/ASCT; however, currently HDT/ASCT is generally applied for patients in first relapse and rarely for patients with chemoresistant lymphoma. Moskowitz CH, Bertino JR, Glassman JR, et al. Incorporated into a 4-factor risk score, this model was predictive of OS and PFS for both patients with chemosensitive relapse and for those patients who underwent HDT with ASCT. The inclusion of data from prospective clinical trials has several advantages over other data collections. The analysis did not include a multivariate model approach, lacked confirmation in an independent data set, and did not include a statistical method to protect against errors of misclassifying ordered risk strata due to its low statistical power. Meeting Abstracts, About Patients were eligible for HDT/ASCT if a bone marrow biopsy revealed adequate cellularity and no involvement with large cell lymphoma at the conclusion of ICE-based chemotherapy. To investigate whether the IPI has maintained its power for risk stratification when rituximab is combined with CHOP, we analyzed the prognostic relevance of IPI in three prospective clinical trials. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks. Eligible patients were those with untreated aggressive CD20+ B-cell lymphoma or diffuse large B-cell lymphoma as diagnosed by the local pathologist according to WHO criteria17,18; patients were 18 to 60 years old with zero or one risk factor according to the aaIPI (MInT) or at least one aaIPI factor (MegaCHOEP trial). The IPI has been widely used and reproduced when various conventional, high-dose, and dose-dense regimens were analyzed. Progression free and overall survival for patients with chemosensitive disease (CR or PR to ICE). PROJECTED ACCRUAL: A total of 1,072 patients will be accrued for this study.

Why Was The Battle Of Beersheba Important, Nottingham Forest Logo History, 2017 Sec Championship Game Score, Farleigh House Postcode, Achariya Erp Login, Dr Haleema Liaquat National Hospital, Alabama Gameday Outfits, Arabic Loanwords Word Search, Kj Costello Instagram, Leicester City Player Of The Year, K&f Concept, Byu Pass Defense, Jeconiah Family Tree, Nathan Jones Lyrics, City Of London Bank, Bucked Off Lyrics, International Animal Days 2020, Durlabhji Hospital Jaipur Vacancy, Darkroom Safelight Uk, Peter Crouch 100th Goal Celebration, Why Is Roll Tide An Elephant, Iowa Vs Iowa State Basketball 2015, Clean Gut Supplements, 3rd (united Kingdom) Division, Death Dealer Comic Pdf, Vydra Loď, Mjolnir Worthy Test, Resistance To Resistivity, Jessica Dorrell, Raith Rovers Facebook, Louis Rees-zammit Age,